In the Boardroom - Teva Pharmaceutical Industries

Filter

Popular Filters

226 to 250 of 274 results

Teva and OncoGenex update on prostate cancer drug development; loss widens at latter

12-03-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals…

BiotechnologycustirsenFinancialLicensingOncoGenexPharmaceuticalResearchTeva Pharmaceutical Industries

Opportunities for Pharma in narcolepsy

20-02-2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Teva Pharma strong sales growth helped by acquisitions

16-02-2012

Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) reported fourth-quarter 2011 results…

CephalonFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Knighthood for GlaxoSmithKline’s Andrew Witty; Teva succession plan

03-01-2012

Andrew Witty, chief executive of UK drug giant GlaxoSmithKline (LSE: GSK) has been awarded a Knighthood…

GenericsGlaxoSmithKlineManagementPharmaceuticalTeva Pharmaceutical Industries

Ring in generics in 2012 and beyond, says Zacks Equity Research

03-01-2012

The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (Nasdaq:…

Dr Reddy's LaboratoriesGenericsMarkets & MarketingNorth AmericaPatentsRanbaxy LaboratoriesSandozTeva Pharmaceutical IndustriesWatson Pharmaceuticals

OPKO Health buys API developer

22-12-2011

Miami, USA-based OPKO Health (NYSE: OPK), which is controlled by Israeli generics giant Teva Pharmaceutical…

FineTech PharmaceuticalGenericsMergers & AcquisitionsOPKO HealthTeva Pharmaceutical Industries

Teva to make massive share buy-back; expects $22 billion sales for 2011

22-12-2011

Israel-based generic drugs giant Teva Pharmaceutical Industries (Nasdaq: TEVA) has announced it plans…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Acino buys more Cephalon/Mepha businesses

19-12-2011

Swiss branded and generic drugmaker Acino Pharma (SIX: ACIN) and Israel’s Teva Pharmaceutical Industries…

Acino PharmaCephalonGenericsMephaMergers & AcquisitionsTeva Pharmaceutical Industries

Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers

30-11-2011

After one year on the market, share of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod),…

AvonexBiogen IdecCopaxoneGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalTeva Pharmaceutical IndustriesTysabri

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint

22-11-2011

Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

Teva to continue selling Viagra generic in Russia

07-11-2011

Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation…

DynamicoEuropeGenericsMarkets & MarketingPatentsPfizerPharmaceuticalReproductiveTeva Pharmaceutical IndustriesViagra

Generics giant Teva posts 3rd-qtr 2011 sales rise but net income down 13%

02-11-2011

The world’s largest generic drugs maker, Teva Pharmaceutical Industries (Nasdaq: TEVA), has reported…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Sanofi to top Pfizer as number one for global pharma sales

01-11-2011

French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst

24-10-2011

Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon

24-10-2011

As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Acino pays 80 million euros for Cephalon’s Middle East and African business

18-10-2011

Switzerland-based generic and branded drugmaker Acino (SIX: ACIN) says it has reached agreement to acquire…

Acino PharmaCephalonGenericsMergers & AcquisitionsPharmaceuticalRest of the WorldTeva Pharmaceutical Industries

Teva gets EU clearance for Cephalon acquisition; negative review on Azilect

14-10-2011

Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA)…

AzilectCephalonMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTeva Pharmaceutical Industries

US antitrust body OKs Teva's acquisition of Cephalon, but with divestments

10-10-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US Federal Trade Commission…

CephalonGenericsLegalMergers & AcquisitionsNorth AmericaPar PharmaceuticalsPharmaceuticalProvigilTeva Pharmaceutical Industries

Generic drugmakers step up presence in Russia, with Dr Reddy’s and Teva planning expansions

03-10-2011

Indian pharmaceutical manufacturers are accelerating their expansion into the Russian market. Following…

Dr Reddy's LaboratoriesEuropeFinancialGenericsMarkets & MarketingTeva Pharmaceutical Industries

Teva buys out partner Kowa’s interest in Japanese JV for $150 million

27-09-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world’s largest generic drugmaker,…

Asia-PacificGenericsKowa PharmaceuticalsMergers & AcquisitionsTeva Pharmaceutical Industries

Teva invests $7.5 million in Cocrystal Discovery for novel hepatitis C antiviral

18-09-2011

In a further move to boost its non-generics activities, Israel’s Teva Pharmaceutical Industries…

Anti-viralsCocrystal DiscoveryLicensingMergers & AcquisitionsPharmaceuticalRegulationTeva Pharmaceutical Industries

Teva ups stake in CureTech to 75% following positive clinical results in lymphoma

14-09-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an…

CureTechGenericsMergers & AcquisitionsOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

226 to 250 of 274 results

Back to top